Trials / Completed
CompletedNCT01907048
Patient and Physician Knowledge of Key Safety Messages
Xarelto (Rivaroxaban) Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,227 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Rivaroxaban (Xarelto, BAY59-7939) | Survey to measure physician awareness and understanding of the key messages in the prescriber guide. |
| BEHAVIORAL | Rivaroxaban (Xarelto, BAY59-7939) | Survey to measure patient awareness and understanding of the key messages in the patient card. |
Timeline
- Start date
- 2014-09-15
- Primary completion
- 2020-02-21
- Completion
- 2020-04-15
- First posted
- 2013-07-24
- Last updated
- 2021-04-08
Locations
4 sites across 4 countries: France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01907048. Inclusion in this directory is not an endorsement.